MBX Biosciences Inc. Comm... (MBX)
MBX Biosciences Common Stock Statistics
Share Statistics
MBX Biosciences Common Stock has 33.42M shares outstanding. The number of shares has increased by null% in one year.
| Shares Outstanding | 33.42M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Institutions (%) | n/a |
| Shares Floating | - |
| Failed to Deliver (FTD) Shares | 61.62K |
| FTD / Avg. Volume | 20.61% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is -9.94 and the forward PE ratio is null. MBX Biosciences Common Stock's PEG ratio is 0.1.
| PE Ratio | -9.94 |
| Forward PE | n/a |
| PS Ratio | 0 |
| Forward PS | n/a |
| PB Ratio | 2.39 |
| P/FCF Ratio | -11.08 |
| PEG Ratio | 0.1 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for MBX Biosciences Common Stock.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 24.19, with a Debt / Equity ratio of 0.
| Current Ratio | 24.19 |
| Quick Ratio | 24.19 |
| Debt / Equity | 0 |
| Debt / EBITDA | 0 |
| Debt / FCF | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-1.44M |
| Employee Count | 43 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by null% in the last 52 weeks. The beta is -0.89, so MBX Biosciences Common Stock's price volatility has been lower than the market average.
| Beta | -0.89 |
| 52-Week Price Change | null% |
| 50-Day Moving Average | 8.6 |
| 200-Day Moving Average | null |
| Relative Strength Index (RSI) | 76.57 |
| Average Volume (20 Days) | 299.06K |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | -68.19M |
| Net Income | -61.92M |
| EBITDA | -67.95M |
| EBIT | -68.19M |
| Earnings Per Share (EPS) | 0 |
Balance Sheet
The company has 49.35M in cash and 171K in debt, giving a net cash position of 49.18M.
| Cash & Cash Equivalents | 49.35M |
| Total Debt | 171K |
| Net Cash | 49.18M |
| Retained Earnings | -137.5M |
| Total Assets | - |
| Working Capital | - |
Cash Flow
In the last 12 months, operating cash flow was -54.68M and capital expenditures -874K, giving a free cash flow of -55.55M.
| Operating Cash Flow | -54.68M |
| Capital Expenditures | -874K |
| Free Cash Flow | -55.55M |
| FCF Per Share | -1.66 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
MBX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for MBX is $38, which is 237.5% higher than the current price. The consensus rating is "Buy".
| Price Target | $38 |
| Price Target Difference | 237.5% |
| Analyst Consensus | Buy |
| Analyst Count | 5 |
Scores
| Altman Z-Score | null |
| Piotroski F-Score | null |